PL2332947T3 - Postaci stałe (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-etoksybenzylo)fenylo)-6-(metylotio)tetrahydro-2H-pirano-3,4,5-triolu i sposoby ich zastosowania - Google Patents

Postaci stałe (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-etoksybenzylo)fenylo)-6-(metylotio)tetrahydro-2H-pirano-3,4,5-triolu i sposoby ich zastosowania

Info

Publication number
PL2332947T3
PL2332947T3 PL11155100T PL11155100T PL2332947T3 PL 2332947 T3 PL2332947 T3 PL 2332947T3 PL 11155100 T PL11155100 T PL 11155100T PL 11155100 T PL11155100 T PL 11155100T PL 2332947 T3 PL2332947 T3 PL 2332947T3
Authority
PL
Poland
Prior art keywords
ethoxybenzyl
triol
pyran
methylthio
tetrahydro
Prior art date
Application number
PL11155100T
Other languages
English (en)
Polish (pl)
Inventor
Susan Margaret De Paul
Anett Perlberg
Matthew Mangzhu Zhao
Original Assignee
Lexicon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals, Inc. filed Critical Lexicon Pharmaceuticals, Inc.
Publication of PL2332947T3 publication Critical patent/PL2332947T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
PL11155100T 2008-07-17 2009-07-15 Postaci stałe (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-etoksybenzylo)fenylo)-6-(metylotio)tetrahydro-2H-pirano-3,4,5-triolu i sposoby ich zastosowania PL2332947T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8142308P 2008-07-17 2008-07-17
EP11155100.8A EP2332947B1 (en) 2008-07-17 2009-07-15 Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use
EP09790436.1 2009-07-15

Publications (1)

Publication Number Publication Date
PL2332947T3 true PL2332947T3 (pl) 2018-04-30

Family

ID=41137707

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11155100T PL2332947T3 (pl) 2008-07-17 2009-07-15 Postaci stałe (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-etoksybenzylo)fenylo)-6-(metylotio)tetrahydro-2H-pirano-3,4,5-triolu i sposoby ich zastosowania

Country Status (29)

Country Link
US (2) US8217156B2 (enExample)
EP (1) EP2332947B1 (enExample)
JP (2) JP2011528366A (enExample)
KR (2) KR20170010069A (enExample)
CN (2) CN107629097A (enExample)
AR (1) AR072807A1 (enExample)
AU (1) AU2009270973B2 (enExample)
BR (1) BRPI0916191A2 (enExample)
CA (1) CA2730931A1 (enExample)
CL (1) CL2009001595A1 (enExample)
CO (1) CO6351797A2 (enExample)
DK (1) DK2332947T3 (enExample)
ES (1) ES2656357T3 (enExample)
HK (1) HK1243713A1 (enExample)
HU (1) HUE035400T2 (enExample)
IL (1) IL210269A (enExample)
MX (1) MX2011000503A (enExample)
NO (1) NO2332947T3 (enExample)
NZ (1) NZ590184A (enExample)
PE (1) PE20100260A1 (enExample)
PL (1) PL2332947T3 (enExample)
PT (1) PT2332947T (enExample)
RU (1) RU2505543C2 (enExample)
SG (1) SG185317A1 (enExample)
TW (1) TWI472521B (enExample)
UA (1) UA106048C2 (enExample)
UY (1) UY31992A (enExample)
WO (1) WO2010009197A1 (enExample)
ZA (1) ZA201100175B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL446852A1 (pl) * 2023-11-27 2025-06-02 Politechnika Rzeszowska im. Ignacego Łukasiewicza Układ doprowadzający wodę do pralki

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
JP5653213B2 (ja) 2007-07-26 2015-01-14 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物
US9061060B2 (en) 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2015123738A (ru) * 2012-11-20 2017-01-10 Лексикон Фармасьютикалз, Инк. Ингибиторы котранспортера натрий-глюкозы 1
CA2922044A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
EP3498723A1 (en) 2015-07-30 2019-06-19 Microbial Chemistry Research Foundation New effective aminoglycoside antibiotic for multidrug-resistant bacteria
CN109195980B (zh) * 2016-05-25 2022-05-17 苏州科睿思制药有限公司 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途
WO2018067805A1 (en) 2016-10-06 2018-04-12 Teva Pharmaceutical Industries Ltd. Solid state forms of sotagliflozin
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
BR112020024296A2 (pt) 2018-08-27 2021-03-09 Regeneron Pharmaceuticals, Inc. Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína
CA3113037A1 (en) * 2018-09-26 2020-04-02 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
PH12021550901A1 (en) 2018-10-29 2022-03-21 Boehringer Ingelheim Int Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN109824687B (zh) * 2019-03-26 2022-03-22 上海凌凯医药科技有限公司 呋喃木糖衍生物的新合成方法
JP7273997B2 (ja) * 2019-07-05 2023-05-15 山東丹紅制薬有限公司 Ｓｇｌｔ阻害剤の結晶形及びその使用
EP3771718A1 (en) * 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Process for preparing the crystalline form ii of sotagliflozin
EP3771480A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
WO2022144465A1 (en) 2021-01-04 2022-07-07 Charité-Universitätsmedizin Berlin Sotagliflozin for improving left atrial function
WO2022155303A1 (en) 2021-01-14 2022-07-21 Lexicon Pharmaceuticals, Inc. Sotagliflozin for treating or preventing cardiovascular diseases
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
US20250108032A1 (en) 2023-09-28 2025-04-03 Lexicon Pharmaceuticals, Inc. Methods of treating type 1 diabetes and kidney disease
US20250114323A1 (en) 2023-10-06 2025-04-10 Lexicon Pharmaceuticals, Inc. Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1856082B1 (en) 2005-02-23 2009-10-14 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
CN1820858A (zh) * 2006-03-10 2006-08-23 广西中医学院制药厂 多相物料喷雾方法及装置
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
JP5653213B2 (ja) * 2007-07-26 2015-01-14 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL446852A1 (pl) * 2023-11-27 2025-06-02 Politechnika Rzeszowska im. Ignacego Łukasiewicza Układ doprowadzający wodę do pralki

Also Published As

Publication number Publication date
KR20170010069A (ko) 2017-01-25
NO2332947T3 (enExample) 2018-03-31
JP2016041701A (ja) 2016-03-31
RU2505543C2 (ru) 2014-01-27
KR101707246B1 (ko) 2017-02-15
JP2011528366A (ja) 2011-11-17
IL210269A (en) 2015-06-30
JP6283337B2 (ja) 2018-02-21
AU2009270973B2 (en) 2014-01-30
NZ590184A (en) 2012-09-28
DK2332947T3 (da) 2018-01-29
CA2730931A1 (en) 2010-01-21
ZA201100175B (en) 2012-03-28
AR072807A1 (es) 2010-09-22
WO2010009197A1 (en) 2010-01-21
US8217156B2 (en) 2012-07-10
RU2011105797A (ru) 2012-08-27
UY31992A (es) 2010-02-26
PE20100260A1 (es) 2010-04-16
SG185317A1 (en) 2012-11-29
US20130165395A1 (en) 2013-06-27
BRPI0916191A2 (pt) 2017-08-29
KR20110031196A (ko) 2011-03-24
MX2011000503A (es) 2011-03-01
EP2332947A1 (en) 2011-06-15
TWI472521B (zh) 2015-02-11
PT2332947T (pt) 2018-02-06
CO6351797A2 (es) 2011-12-20
CN107629097A (zh) 2018-01-26
CN102112483A (zh) 2011-06-29
HUE035400T2 (en) 2018-05-02
ES2656357T3 (es) 2018-02-26
US20100016422A1 (en) 2010-01-21
AU2009270973A1 (en) 2010-01-21
EP2332947B1 (en) 2017-11-01
TW201006808A (en) 2010-02-16
HK1243713A1 (zh) 2018-07-20
CL2009001595A1 (es) 2010-07-19
UA106048C2 (uk) 2014-07-25
IL210269A0 (en) 2011-03-31
US9067962B2 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
ZA201100175B (en) Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use
PT2661256T (pt) Composições compreendendo (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetra-hidro-2h-pirano-3,4,5-triol
PL2187742T3 (pl) Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy
PT2707366E (pt) Co-cristais com l-prolina e ácido cítrico de (2s,3r,4r, 5s,6r)-2-(3-((5-(4-fluorofenil)tiofen-2-il)metil)-4-metilfenil)-6- (hidroximetil tetrahidro-2h-pirano-3,4,5-triol
IL191045A0 (en) Spinal motion preservation assemblies
IL188360A0 (en) Secure hardware desktop buffer composition
SI2068891T1 (sl) Sestavek, ki obsega gastrolitne komponente rakov, kalcijev karbonat, in njegova uporaba
NZ589517A (en) A pharmaceutical composition comprising rebamipide
NZ630408A (en) Process for preparation of benzylbenzene sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
IL199181A (en) The crystalline form of a monosulfate salt of 2– chloro – 4– [1– (4 – fluoro – phenyl) –2,5 – dimethyl– h1– imidazole – 4 – ylethinyl] –pyridine, its pharmaceutical preparations and uses
IL192425A0 (en) Carbonates of fenicol antibiotics
PL1951879T3 (pl) Rośliny o podwyższonej zawartości aminocukrów
WO2012173410A3 (en) Novel c-aryl ansa sglt2 inhibitors
IL206337A0 (en) Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
ZA200802625B (en) Plants having an increased content of amino sugars
ZA200807701B (en) Differentiating therapeutic composition
TH122363A (th) รูปแบบที่เป็นของแข็งของ (2s, 3r, 4r, 5s, 6r)-2-(4-คลอโร-3-(4-เอทธอกซีเบนซิล)-ฟีนิล)-6-(เมทธิลไธโอ)เตตราไฮโดร-2-h-ไพราน-3,4,5-ไตรออล และวิธีการของการใช้สิ่งเหล่านี้
ZA200805673B (en) Carbonates of fenicol antibiotics
EP1833491A4 (en) TOPICAL COMPOSITIONS WITH ONE OR MORE 44-THIURIDINE, ISOMALTITOL AND URIDINE
ZA200703308B (en) Improvements to high speed uplink packet access scheme
AU2005903359A0 (en) Treatment of sheep to reduce flystrike
BRPI0618927A2 (pt) composição de condimento, e, método para conferir um perfil temporal mais parecido com o do açúcar, um perfil de flavor mais parecido com o do açúcar ou ambos a uma composição de condimento
HK1149016A (en) Novel cytostatic 7-deazapurine nucleosides
PL380678A1 (pl) Kompozycja soku, nektaru lub napoju i jej zastosowanie
GB0505368D0 (en) Universal window of accelerating action